SUBSCRIBE: / eNewsletter
Expanded role for MRI and 2 recently approved treatment options. (©Gemalbarra/Shutterstock.com)
Psoriasis and psoriatic arthritis have long been associated with cardiovascular disease and deaths, but now a large population study from Taiwan indicates the danger of cardiac arrhythmias is increased independently of traditional risk factors such as coronary disease and high blood pressure.
Here is the case of a 30-year-old man with scalp psoriasis in whom Koebner phenomenon developed at areas of developing shingles.
The news from phase 3 trials of psoriatic arthritis treatments is upbeat: certolizumab pegol (Cimzia), apremilast (Otezla), and secukinumab (Cosentyx) all continue to show positive effects.
The goal of 90% skin clearance is “reachable” for many patients with severe psoriasis with interleukin-17 (IL-17) inhibitors. A closer look here.
Intensive treatment with statins may help reduce risk of cardiovascular events in patients with inflammatory arthritis, suggests a new study.
This article reviews topical and systemic treatments for uncomplicated psoriasis.
Patients with psoriatic arthritis achieve significant improvements in signs and symptoms with the interleukin-12/23 inhibitor ustekinumab (Stelara), and they maintain those gains for 2 years, according to final results from 3 major clinical trials.
This overview of NSAIDs, corticosteroids, DMRDs, PDE4 inhibitors, and biologic agents offers recommendations for first-line options for mild and moderate-to-severe psoriatic arthritis.
The first study to assess the effects of DMARDs or anti-TNF treatment in a real world population of patients with inflammatory arthritis shows a clinically significant improvement in work disability, productivity loss, and disease activity-- especially in those receiving TNF-α blockers.
In a 12-week phase 3 trial, tofacitinib,10 mg twice a day, was non-inferior to etanercept, 50 mg twice a week. Tofacitinib, 5 mg twice a day, was inferior to etanercept.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
